The first FDA-approved PROTAC strengthens the case for LYTACs and the next generation of extracellular degraders

The first FDA approval of a PROTAC has just landed. On 1 May 2026, the agency cleared Arvinas and Pfizer’s vepdegestrant (Veppanu) for adults with ESR1-mutant, ER-positive, HER2-negative advanced breast cancer, ahead of its PDUFA date and on the strength of a 43% reduction in the risk of disease progression versus fulvestrant in the Phase 3 VERITAC-2 trial. After two decades of work tracing back to Craig Crews and Ray Deshaies’ original 2001 chimaera, an event-driven, catalytic degrader has cleared the regulatory bar. Targeted protein degradation has now been proven not only as a chemical biology tool, but as a medicine.

That medicine, however, works inside the cell. PROTACs hijack the ubiquitin-proteasome system, so by design they reach only intracellular targets. Roughly forty percent of the human proteome sits outside that compartment, on the plasma membrane or in the extracellular milieu, and the proteasome cannot touch any of it. Closing that gap requires a different cellular machinery altogether: receptor-mediated endocytosis and the lysosome.

“This milestone demonstrates that targeted protein degradation can translate into meaningful clinical impact.”

That alternative arrived in 2020 with LYTACs, bifunctional molecules that tether an extracellular target to a lysosome-shuttling receptor such as the cation-independent mannose-6-phosphate receptor or, in the liver, the asialoglycoprotein receptor. The toolkit has expanded fast: AbTACs and PROTABs co-opt cell-surface E3 ligases like RNF43 and ZNRF3; KineTACs route cargo through cytokine receptors; ATACs use peptide warheads against integrins. Most recently, Huang, Bertozzi, and Baker reported computationally designed EndoTags that trigger endocytosis without any native ligand, making fully genetically encoded degraders feasible.

The implications track with the proteome itself. Cytokines, immune checkpoints, secreted oncogenic ligands, and tumour cell-surface receptors that resisted both small-molecule and antibody approaches now have a credible degradation path, as catalogued in a recent comprehensive review of eTPD design diversity. Vepdegestrant’s clearance will not, on its own, derisk LYTACs in the clinic; biodistribution, manufacturability, and immunogenicity remain real engineering problems. But it does establish that regulators will approve degraders on the same evidentiary basis as any other oncology agent. For the wave of extracellular degraders now entering IND-enabling studies, that is the validation the field was waiting for.